Kathleen R King

US Patent:

6632979, Oct 14, 2003

Filed:

Mar 16, 2001

Appl. No.:

09/811115

Inventors:

Sharon Erickson - Hillsborough CA
Kathleen King - Pacifica CA
Ralph Schwall - Pacifica CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A01K 67027

US Classification:

800 18, 800 8, 800 9, 800 10, 800 3, 435455, 435463, 435325, 4353201

Abstract:

The invention concerns HER -transgenic non-human mammals, animal models for screening drug candidates for the treatment of diseases and disorders associated with the overexpression of HER. In particular, the invention concerns animal models designed to test drug candidates for the treatment of HER -overexpressing cancers, including breast cancer, that are not responding or poorly responding to current treatments.

US Patent:

6653287, Nov 25, 2003

Filed:

Sep 13, 2000

Appl. No.:

09/660590

Inventors:

Napoleone Ferrara - San Francisco CA
Kathleen King - Pacifica CA
Elizabeth Luis - San Francisco CA
Jennie P. Mather - Millbrae CA
Nicholas F. Paoni - Belmont CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 3817

US Classification:

514 21, 514 2, 530300, 530350

Abstract:

A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.

US Patent:

20020137189, Sep 26, 2002

Filed:

Jun 29, 2001

Appl. No.:

09/896856

Inventors:

Joffre Baker - El Granada CA, US
Kenneth Chien - La Jolla CA, US
Kathleen King - Pacifica CA, US
Diane Pennica - Burlingame CA, US
William Wood - San Mateo CA, US

Assignee:

Genentech, Inc.

International Classification:

C12Q001/68
C07H021/04
C12N009/64
C12N001/21
C12N005/06

US Classification:

435/252300, 435/325000, 435/226000, 435/006000, 536/023200, 435/320100

Abstract:

Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

US Patent:

20030054550, Mar 20, 2003

Filed:

Mar 26, 2002

Appl. No.:

10/107931

Inventors:

Joffre Baker - El Granada CA, US
Kenneth Chien - La Jolla CA, US
Kathleen King - Pacifica CA, US
Diane Pennica - Burlingame CA, US
William Wood - San Mateo CA, US

Assignee:

Genentech, Inc.

International Classification:

C12N005/08
A61K009/127

US Classification:

435/368000, 424/450000

Abstract:

Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

US Patent:

20040006018, Jan 8, 2004

Filed:

Apr 3, 2003

Appl. No.:

10/407303

Inventors:

Joffre Baker - El Granada CA, US
Kenneth Chien - La Jolla CA, US
Kathleen King - Pacifica CA, US
Diane Pennica - Burlingame CA, US
William Wood - San Mateo CA, US

Assignee:

Genentech, Inc.

International Classification:

A61K038/18
C12N005/08
C12N005/06

US Classification:

514/012000, 435/366000, 435/325000

Abstract:

Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. CT-1 is shown to bind to and activate the receptor, LIFR. These CT-1 molecules are shown to influence hypertrophic activity, neurological activity, and other activities associated with receptor LIFR. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, neurological disorders, and other disorders associated with the LIFR.

US Patent:

20040116678, Jun 17, 2004

Filed:

Nov 24, 2003

Appl. No.:

10/722095

Inventors:

Joffre Baker - El Granada CA, US
Kenneth Chien - La Jolla CA, US
Kathleen King - Pacifica CA, US
Diane Pennica - Burlingame CA, US
William Wood - San Mateo CA, US

International Classification:

C07K014/475
G01N033/53
C07H021/04
C07K016/22

US Classification:

530/399000, 530/388250, 435/069100, 435/320100, 435/353000, 435/007100, 536/023500

Abstract:

Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

US Patent:

55716750, Nov 5, 1996

Filed:

May 17, 1995

Appl. No.:

8/444083

Inventors:

Joffre Baker - El Granada CA
Kenneth Chien - La Jolla CA
Kathleen King - Pacifica CA
Diane Pennica - Burlingame CA
William Wood - San Mateo CA

Assignee:

Genentech, Inc. - South San Francisco CA
Regents of the Univ. of California - Oakland CA

International Classification:

C12Q 168
C12P 1934
C07H 2104

US Classification:

435 6

Abstract:

Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

US Patent:

58372415, Nov 17, 1998

Filed:

Jul 26, 1996

Appl. No.:

8/693826

Inventors:

Napoleone Ferrara - San Francisco CA
Kathleen King - Pacifica CA
Elizabeth Luis - San Francisco CA
Jennie P. Mather - Millbrae CA
Nicholas F. Paoni - Belmont CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39395
C12N 512
C07K 1618
C07K 1622

US Classification:

4241361

Abstract:

A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.